United Therapeutics Corporation Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent
United Therapeutics Corporation (UTHR) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent of -$1.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent · last filed 2026-08-05
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.90M, a 480.00% decline year-over-year.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2026-03-31 was -$3.50M, a 305.88% decline year-over-year.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2025-12-31 was $300.00K.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for the quarter ending 2025-09-30 was $700.00K, a 90.79% decline year-over-year.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2025 was $3.20M, a 13.51% decline from fiscal 2024.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2024 was $3.70M, a 74.66% decline from fiscal 2023.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2023 was $14.60M.
- United Therapeutics Corporation other comprehensive income (loss), available-for-sale securities, tax, portion attributable to parent for fiscal 2022 was -$16.30M.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.90M 10-Q · filed 2026-08-05 | -$5.40M 10-Q · filed 2026-08-05 | -$5.10M derived: sum of 3 quarters · filed 2026-08-05 | -$4.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.50M 10-Q · filed 2026-05-06 | -$3.20M derived: sum of 2 quarters · filed 2026-05-06 | -$2.50M derived: sum of 3 quarters · filed 2026-05-06 | -$2.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.00M derived: sum of 2 quarters · filed 2026-02-25 | $1.50M derived: sum of 3 quarters · filed 2026-08-05 | $3.20M 10-K · filed 2026-02-25 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-10-29 | $1.20M derived: sum of 2 quarters · filed 2026-08-05 | $2.90M 10-Q · filed 2025-10-29 | -$400.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $500.00K 10-Q · filed 2026-08-05 | $2.20M 10-Q · filed 2026-08-05 | -$1.10M derived: sum of 3 quarters · filed 2026-08-05 | $6.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.70M 10-Q · filed 2026-05-06 | -$1.60M derived: sum of 2 quarters · filed 2026-05-06 | $6.00M derived: sum of 3 quarters · filed 2026-05-06 | $6.60M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.30M derived: sum of 2 quarters · filed 2026-02-25 | $4.90M derived: sum of 3 quarters · filed 2026-02-25 | $3.70M 10-K · filed 2026-02-25 |
| 2024-09-30 | $7.60M 10-Q · filed 2025-10-29 | $8.20M derived: sum of 2 quarters · filed 2025-10-29 | $7.00M 10-Q · filed 2025-10-29 | $16.40M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $600.00K 10-Q · filed 2025-07-30 | -$600.00K 10-Q · filed 2025-07-30 | $8.80M derived: sum of 3 quarters · filed 2026-02-25 | $11.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$1.20M 10-Q · filed 2025-04-30 | $8.20M derived: sum of 2 quarters · filed 2026-02-25 | $10.70M derived: sum of 3 quarters · filed 2026-02-25 | $7.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.90M derived: sum of 2 quarters · filed 2026-02-25 | $8.30M derived: sum of 3 quarters · filed 2026-02-25 | $14.60M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.50M 10-Q · filed 2024-10-30 | -$1.10M derived: sum of 2 quarters · filed 2024-10-30 | $5.20M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | -$3.60M 10-Q · filed 2024-07-31 | $2.70M 10-Q · filed 2024-07-31 | ||
| 2023-03-31 | $6.30M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | -$16.30M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$4.60M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |